(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 November 2016 (24.11.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/187546 A1

(51) International Patent Classification:
A61P 37/06 (2006.01) *C12N 15/13* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2016/033544

(22) International Filing Date:
20 May 2016 (20.05.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/164,206 20 May 2015 (20.05.2015) US
62/214,586 4 September 2015 (04.09.2015) US

(71) Applicants: **JANSSEN BIOTECH, INC.** [US/US]; 800/850 Ridgeview Drive, Horsham, PA 19044 (US). **TUFTS MEDICAL CENTER, INC.** [US/US]; 800 Washington Streeet, Boston, Massachusetts 02111 (US).

(72) Inventors: **DOSHI, Parul**; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). **SASSER, Amy**; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). **CHAULAGAIN, Chakra**; 800 Washington Street, Boston, Massachusetts 02111 (US). **COMENZO, Raymond**; 800 Washington Street, Boston, Massachusetts 02111 (US). **MA, Xun**; 800 Washington Street, Boston, Massachusetts 02111 (US).

(74) Agents: **SHIRTZ, Joseph F.** et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: ANTI-CD38 ANTIBODIES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS AND OTHER CD38-POSITIVE HEMATOLOGICAL MALIGNANCIES

(57) Abstract: The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.

Figure 1.



WO 2016/187546 A1

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*